NCT06511063招募中2 期
Investigating the Feasibility of Repurposing HIV Antivirals in Adults With Long Covid
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 90
- 试验地点
- 2
- 主要终点
- EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale
研究概览
简要总结
The trial will test if two repurposed HIV antivirals can reduce symptom burden in adult participants with Long Covid compared to placebo. Viral infection and viral reactivation have been documented in Long Covid.
Participants will be randomly allocated to receive antivirals, Truvada (tenofovir disoproxil/emtricitabine, TDF/FTC, Group 1) or Selzentry (Group 2), or a placebo (pill) (Group 3), taken daily for 90 days.
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Other
- 盲法
- Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Provision of signed and dated informed consent form
- •Stated willingness to comply with all study procedures and availability for the duration of the study
- •Any gender, aged 18+
- •Diagnosed with:
- •Long Covid
- •Documented clinical history of confirmed or suspected acute SARS-CoV-2 infection a minimum of 6 months prior to contact with the study team
- •Formal diagnosis of Long Covid from a physician and a history of 6 months of Long COVID symptoms
- •At least a six-month history of one of the following symptoms following SARS-CoV-2 infection:
- •headache, memory loss, insomnia, mood disturbance, chest pain, palpitations, shortness of breath, cough, muscle pains, joint pains, or GI upset] AND at least moderate fatigue (measured by Fatigue Severity Score) AND at least moderate post-exertional malaise (PEM) (measured by DePaul PEM screener)
- •Participants who are willing and able to comply with all data collection, treatment plan, laboratory tests, lifestyle considerations, and other study procedures.
- •Baseline EQ-VAS ≤70; EQ-VAS before the index infection ≥80 (this information is collected before randomization as part of the baseline survey).
排除标准
- •Pre-existing conditions including, but not limited to:
- •Autoimmune conditions such as Chronic EBV, Multiple Sclerosis, Hashimoto's Disease, etc. which would impact the immunological profiling analysis.
- •A pre-2020 diagnosis of another Post-Acute Infectious Syndrome such as Chronic Lyme disease, Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, etc.
- •Documented history of vaccine injury
- •Or any other chronic condition that has the potential to impact on immunological profiling, at the discretion of the research physician
- •HIV+ status
- •Current use of either Truvada or Selzentry
- •Taking a medication, within 6 weeks, with known interactions with Truvada or Selzentry including but not limited to: Acyclovir, valacyclovir, adefovir, cabozantinib, carbamazepine, cidofovir, cladribine, cobicistat, diclofenac, multiple NSAIDs or chronic high dose NSAIDs, fosphenytoin or phenytoin, ganciclovir, valganciclovir, oxcarbazepine, phenobarbital, primidone, rifabutin, rifampin, rifapentine, sofosbuvir, tipranavir, or other drugs that significantly affect renal function
- •Current treatment with drugs known to affect EBV replication, including but not limited to: Acyclovir, valacyclovir, ganciclovir, valganciclovir, famciclovir, teriflunomide, interferon
- •Known allergic reactions to components of Truvada or Selzentry
- •Febrile illness within the last 3 months of planned baseline evaluation
- •Treatment with another investigational drug or other investigational intervention within 6 months of planned baseline evaluation
- •Immunosuppressed individuals (transplant on antiviral prophylaxis and/or patients taking immunosuppressive medications such as steroids, etc.)
- •Known medical history of active liver disease (other than nonalcoholic hepatic steatosis), including chronic or active hepatitis B or C infection, primary biliary cirrhosis, Child-Pugh Class B or C, or acute liver failure
- •Receiving dialysis or have known renal impairment
- •Any comorbidity requiring hospitalization and/or surgery within 7 days prior to study entry, or that is considered life threatening within days prior to study entry, as determined by the study team
- •Other medical or psychiatric conditions, in the treating investigator's judgment, that makes the participant inappropriate for the study
- •Unknown HIV status (subjects must have completed HIV antigen/antibody and viral load testing completed at the screening visit)
- •Active or latent hepatitis B (subjects must have completed HBV serologies - HbsAg, anti-HBs, and anti-HBc - testing completed at the screening visit)
- •Current symptoms of severe, progressive, or uncontrolled renal, hematologic, gastrointestinal, pulmonary, cardiac, or neurologic disease, or other medical conditions that, in the opinion of the investigator, might place the subject at unacceptable risk for participation in this study
- •Creatinine clearance (CrCl) <75mL/min, as calculated by the Cockcroft-Gault equation
- •Any history of bone fractures not explained by trauma
- •Confirmed Grade 2 or greater hypophosphatemia
- •Any Grade 2 or greater toxicity on screening tests and assessments
研究组 & 干预措施
Truvada (Tenofovir Disoproxil Fumarate, TDF/FTC, tenofovir disoproxil/emtricitabine)
Experimental
Participants will take 300mg tenofovir disoproxil fumarate/200 mg emtricitabine, once per day, and one placebo capsule per day, oral capsule for 90 days.
干预措施: tenofovir disoproxil/emtricitabine (Drug)
Truvada (Tenofovir Disoproxil Fumarate, TDF/FTC, tenofovir disoproxil/emtricitabine)
Experimental
Participants will take 300mg tenofovir disoproxil fumarate/200 mg emtricitabine, once per day, and one placebo capsule per day, oral capsule for 90 days.
干预措施: Placebo (Drug)
Selzentry
Experimental
Participants will take 300 mg of Selzentry, twice a day, oral capsule for 90 days.
干预措施: Selzentry (Drug)
Placebo
Placebo Comparator
Participants will take a placebo, twice per day, oral capsule for 90 days.
干预措施: Placebo (Drug)
结局指标
主要结局
EuroQol 5-Dimension 5-Level (EQ-5D-5L) Visual Analogue Scale
时间窗: at Screening, Day 60, Day 90, and Day 180
The EQ-5D-5L is a standardized measure of health status that consists of 5 dimensions (mobility, self-care, usual activities, pain/discomfort, anxiety/depression) each with 5 levels of severity, and a visual analogue scale (VAS) where individuals rate their overall health from 0 (worst imaginable health) to 100 (best imaginable health).
次要结局
- The EuroQol Five-Dimensional Health Questionnaire (EQ-5D-5L)(at Screening, Day 60, Day 90, and Day 180)
- Patient-Reported Outcomes Measurement Information System 29 (PROMIS-29)(at Screening, Day 60, Day 90, and Day 180)
- General Symptom Questionnaire (GSQ-30)(at Screening, Day 60, Day 90, and Day 180)
- Fatigue Visual Analogue Scale (F-VAS)(at Screening, Day 60, Day 90, and Day 180)
- DePaul Post-Exertional Malaise Questionnaire (DSQ)(at Screening, Day 60, Day 90, and Day 180)
- Composite Autonomic Symptom Score 31(COMPASS-31)(at Screening, Day 60, Day 90, and Day 180)
- Patient Health Questionnaire (PHQ-9)(at Screening, Day 60, Day 90, and Day 180)
- Generalized Anxiety Disorder (GAD-7)(at Screening, Day 60, Day 90, and Day 180)
- Neuro-QoL™ v2.0 Cognitive Function-Short Form(at Screening, Day 60, Day 90, and Day 180)
- Single-item Sleep Quality Scale (SQS)(at Screening, Day 60, Day 90, and Day 180)
- Fatigue Severity Scale (FSS)(at Screening, Day 60, Day 90, and Day 180)
- Pain Visual Analogue Scale (P-VAS)(at Screening, Day 60, Day 90, and Day 180)
研究者
David Putrino
Professor
Icahn School of Medicine at Mount Sinai
研究点 (2)
Loading locations...
相似试验
已完成
不适用
Addition of Ezetimibe (Ezetrol®) to Ongoing Therapy With Rosuvastatin (Crestor®) in HIV Positive Patients Not Reaching Cholesterol TargetsHypercholesterolemiaHIV InfectionsNCT00908011University of British Columbia43
已完成
2 期
A Study of a Combination of Four Drugs in Patients With Recent HIV InfectionHIV InfectionsNCT00002233Glaxo Wellcome30
已完成
4 期
Double Protease Inhibitor to Darunavir Switch StudyHIV InfectionsNCT00531557St Stephens Aids Trust12
已完成
2 期
A Study on Amprenavir in Combination With Other Anti-HIV Drugs in HIV-Positive PatientsHIV InfectionsNCT00000912National Institute of Allergy and Infectious Diseases (NIAID)475
已完成
2 期
Effectiveness of ABT-378/Ritonavir Plus Lamivudine Plus Efavirenz Plus Tenofovir DF in HIV-Infected PatientsHIV InfectionsNCT00038220Abbott40